Hemab Therapeutics (NASDAQ:COAG) Stock Price Up 8.4% - Here's What Happened

Key Points

• Hemab Therapeutics shares rose 8.4% to $32.46, although trading volume was 64% below the stock’s average daily volume.
• Analyst sentiment remains broadly positive, with seven Buy ratings, one Hold and one Sell; the consensus rating is “Moderate Buy” with an average price target of $54.71.
• The company reported a quarterly loss of $0.80 per share, missing expectations by $0.17, while several institutional investors—including Citadel Advisors and Braidwell—established new positions.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report)'s stock price shot up 8.4% during trading on Thursday. The stock traded as high as $32.55 and last traded at $32.46. Approximately 136,454 shares changed hands during trading, a decline of 64% from the average daily volume of 378,583 shares. The stock had previously closed at $29.94.

Wall Street Analysts Forecast Growth

COAG has been the subject of a number of analyst reports. Jefferies Financial Group upped their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the stock a "buy" rating in a report on Monday, July 13th. Weiss Ratings lowered shares of Hemab Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research note on Friday, September 25th. Rodman & Renshaw assumed coverage on shares of Hemab Therapeutics in a research report on Monday. They set a "buy" rating and a $56.00 target price on the stock. JPMorgan Chase & Co. initiated coverage on shares of Hemab Therapeutics in a research note on Thursday. They issued an "overweight" rating and a $70.00 target price for the company. Finally, HC Wainwright upped their target price on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Hemab Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $54.71.

Hemab Therapeutics Stock Performance

The firm has a market cap of $1.51 billion and a price-to-earnings ratio of -1.31. The firm has a 50 day moving average price of $41.66.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Research analysts forecast that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current year.

Institutional Trading of Hemab Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in COAG. Citadel Advisors LLC bought a new position in Hemab Therapeutics during the 2nd quarter valued at $19,226,000. Braidwell LP acquired a new position in Hemab Therapeutics during the 2nd quarter worth $5,877,000. State Street Corp bought a new stake in shares of Hemab Therapeutics in the 2nd quarter worth about $2,825,000. Opaleye Management Inc. bought a new stake in shares of Hemab Therapeutics in the 2nd quarter worth about $1,750,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Hemab Therapeutics in the 2nd quarter worth about $688,000.

About Hemab Therapeutics

Hemab Therapeutics NASDAQ: COAG is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.

Hemab's lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.